DA
Therapeutic Areas
Syndax Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Revumenib (SNDX-5613) | KMT2A-r Acute Leukemia (AML, ALL, MPS) | Phase 2/3 |
| Axatilimab (SNDX-6352) | Chronic Graft-versus-Host Disease (cGVHD) | Phase 2/3 |
| Revumenib + Ven/Aza | Frontline AML (KMT2Ar or NPM1m) | Phase 1b |
Leadership Team at Syndax Pharmaceuticals
MA
Michael A. Metzger
Chief Executive Officer, Director
KA
Keith A. Goldan
Chief Financial Officer, Treasurer
NG
Neil Gallagher
President, Head of Research and Development
BB
Brigitte B. Robertson
Chief Medical Officer
DG
Dennis G. Hall
Chief Scientific Officer
KA
Keith A. Katkin
Chairman of the Board